Premium
Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil
Author(s) -
Cetkovská Petra,
Pizinger Karel
Publication year - 2006
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2004.02472.x
Subject(s) - medicine , terbinafine , mycophenolate , exacerbation , dermatology , methylprednisolone , lupus erythematosus , subacute cutaneous lupus erythematosus , systemic lupus erythematosus , systemic disease , connective tissue disease , immunology , autoimmune disease , disease , transplantation , antibody , antifungal , itraconazole
A 39‐year‐old female patient with systemic lupus erythematosus was treated with terbinafine for onychomycosis. After only 7 days of treatment with 250 mg terbinafine, a widespread severe erythematous eruption developed. The results of clinical, histological and immunofluorescent examinations confirmed the diagnosis of coexisting subacute and systemic lupus erythematosus. The patient was treated with drug withdrawal and administration of cyclosporine and methylprednisolone. One year later, mycophenolate mofetil was successfully used . Exacerbation or induction of lupus erythematosus is an extremely rare cutaneous side‐effect of terbinafine. Patients with lupus erythematosus should be advised about the risk of some drugs that might exacerbate their disease.